文献速递胸部肿瘤

国际肺癌研究协会关于2019冠状病毒病对国际肺癌临床试验影响的研究

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials.
PubMed 文献 · J Thorac Oncol · 2022-02-17

该研究通过数据收集调查和行动调查评估COVID-19对全球肺癌试验的影响。2019至2020年全球入组下降14%,主要发生在4至6月,单个中心入组显著减少(p=0.0309);最常见挑战为合格患者减少(63%)、方案依从性下降(56%)和试验暂停(54%)。缓解策略包括远程医疗访视(45%)等,最有效策略为远程知情同意(89%)、远程医疗访视(85%)等。

要点

  • 2019至2020年全球肺癌试验入组下降14%,主要发生在4至6月。
  • 行动调查(N=172)显示最常见挑战为合格患者减少(63%)、方案依从性下降(56%)、试验暂停(54%)。
  • 最有效缓解策略包括远程知情同意(89%)、远程医疗访视(85%)、远程患者报告症状收集(85%)、院外操作(85%)。

核心结论

  • COVID-19大流行给肺癌临床试验的实施和入组带来了许多挑战。
  • 尽管大流行恶化,试验入组有所改善。
  • 作者认为更灵活的方法可能改善入组和临床试验的可及性,甚至在大流行之后也是如此。

研究设计与样本

  • 数据收集调查收集了2019至2020年294项全球肺癌试验的每月汇总入组数据。
  • 64个问题的行动调查评估了COVID-19对临床试验的影响并确定了实施的缓解策略(N=172)。

主要发现

  • 2019至2020年全球临床试验入组下降14%。
  • 入组减少主要发生在4至6月,单个中心入组显著减少(p=0.0309)。
  • 2019年10月至12月与2020年同期入组无显著差异(p=0.25)。
  • 行动调查(N=172)中最常见挑战为合格患者减少(63%)、方案依从性下降(56%)、试验暂停(54%)。
  • 患者相关挑战包括进入试验中心(49%)、旅行能力(54%)、访问中心意愿(59%)。

关键数值与推荐

  • 最常见缓解策略包括修改监测要求(47%)、远程医疗访视(45%)、修改所需访视(25%)、邮购药物(25%)、在非研究机构进行实验室(27%)和放射学(21%)检查。
  • 中心认为最有效的缓解策略为远程医疗访视(85%)、远程患者报告症状收集(85%)、院外操作(85%)、远程知情同意(89%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To evaluate the effects of the global coronavirus disease 2019 (COVID-19) pandemic on lung cancer trials, we surveyed investigators and collected aggregate enrollment data for lung cancer trials across the world before and during the pandemic. METHODS: A Data Collection Survey collected aggregate monthly enrollment numbers from 294 global lung cancer trials for 2019 to 2020. A 64-question Action Survey evaluated the impact of COVID-19 on clinical trials and identified mitigation strategies implemented. RESULTS: Clinical trial enrollment declined from 2019 to 2020 by 14% globally. Most reductions in enrollment occurred in April to June where we found significant decreases in individual site enrollment (p = 0.0309). Enrollment was not significantly different in October 2019 to December of 2019 versus 2020 (p = 0.25). The most frequent challenges identified by the Action Survey (N = 172) were fewer eligible patients (63%), decrease in protocol compliance (56%), and suspension of trials (54%). Patient-specific challenges included access to trial site (49%), ability to travel (54%), and willingness to visit the site (59%). The most frequent mitigation strategies included modified monitoring requirements (47%), telehealth visits (45%), modified required visits (25%), mail-order medications (25%), and laboratory (27%) and radiology (21%) tests at nonstudy facilities. Sites that felt the most effective mitigation strategies were telehealth visits (85%), remote patient-reported symptom collection (85%), off-site procedures (85%), and remote consenting (89%). CONCLUSIONS: The COVID-19 pandemic created many challenges for lung cancer clinical trials conduct and enrollment. Mitigation strategies were used and, although the pandemic worsened, trial enrollment improved. A more flexible approach may improve enrollment and access to clinical trials, even beyond the pandemic.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Smeltzer MP, Scagliotti GV, Wakelee HA, et al. International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials. J Thorac Oncol. 2022. PMID: 35183774. doi:10.1016/j.jtho.2022.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。